Novo Nordisk A/S NVO releases its next round of earnings this Thursday, Nov. 1. Here's Benzinga's essential guide to Novo Nordisk's Q3 earnings report.
Earnings and Revenue
Wall Street expects EPS of 61 cents and sales around $4.39 billion.
Novo Nordisk EPS in the same period a year ago totaled 62 cents. Sales were $4.15 billion. If the company were to report inline earnings when it publishes results Thursday, earnings would be down 1.61 percent. Revenue would be up 5.73 percent from the year-ago period. Here's how the company's EPS has stacked up against analyst estimates in the past:
| Quarter | Q2 2018 | Q1 2018 | Q4 2017 | Q3 2017 |
| EPS Estimate | 0.65 | 0.57 | 0.61 | |
| EPS Actual | 0.68 | 0.73 | 0.53 | 0.62 |
Stock Performance
Over the last 52-week period, shares are down 14 percent. Given that these returns are generally negative, long-term shareholders are probably unhappy going into this earnings release.
Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. The popular rating by analysts on Novo Nordisk stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
Novo Nordisk's Q3 conference call is scheduled to begin at 2:00 p.m. ET and can be accessed here: https://edge.media-server.com/m6/p/ziw3xey8
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
